KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Receivables: 2010-2024

Historic Receivables for Novavax (NVAX) over the last 13 years, with Dec 2024 value amounting to $121.4 million.

  • Novavax's Receivables fell 56.77% to $47.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $466.1 million, marking a year-over-year decrease of 6.01%. This contributed to the annual value of $121.4 million for FY2024, which is 61.56% down from last year.
  • According to the latest figures from FY2024, Novavax's Receivables is $121.4 million, which was down 61.56% from $315.7 million recorded in FY2023.
  • Over the past 5 years, Novavax's Receivables peaked at $490.3 million during FY2021, and registered a low of $121.4 million during FY2024.
  • Its 3-year average for Receivables is $187.3 million, with a median of $124.8 million in 2022.
  • Per our database at Business Quant, Novavax's Receivables soared by 3,393.49% in 2020 and then plummeted by 74.54% in 2022.
  • Novavax's Receivables (Yearly) stood at $262.0 million in 2020, then spiked by 87.13% to $490.3 million in 2021, then slumped by 74.54% to $124.8 million in 2022, then soared by 152.96% to $315.7 million in 2023, then plummeted by 61.56% to $121.4 million in 2024.